Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Used mainly for the management of neuropathic pain, pregabalin is a gabapentinoid or anticonvulsant that was initially developed as an antiepileptic agent. After more than a decade of experience with pregabalin, experience and studies have shown that the adverse effect profile of pregabalin is well tolerated for the management of neuropathic pain and other conditions. Its use is associated with benign central nervous system and systemic adverse effects, and there are very limited metabolic, idiosyncratic or known teratogenic adverse effects. Along with its efficacy in particular neuropathic pain conditions, pregabalin’s safety led it to be one of the first pharmacotherapies considered for the management of neuropathic pain. This review discusses the use of pregabalin as well as its potential adverse effects, including the most commonly noted features of sedation, dizziness, peripheral edema and dry mouth. Although other adverse effects may occur, these appear to be uncommon. The review also discusses the clinical implications of pregabalin’s use for the clinician.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Eroglu, Ç., Allen, N. J., Susman, M. W., O'Rourke, N. A., Park, C. Y., Özkan, E., Chakraborty, C., Mulinyawe, S. B., Annis, D. S., Huberman, A. D., et al. (2009) · Cell · doi:10.1016/j.cell.2009.09.025 · Cited by 893 · cited 3×
“2009], even though other potential mechanisms may also occur [Eroglu et al. 2009].”
BackgroundTreatment of neuropathic pain: an overview of recent guidelines.
O'Connor, A. B., & Dworkin, R. H. (2009) · The American Journal of Medicine · doi:10.1016/j.amjmed.2009.04.007 · Cited by 781
Arnold, L. M., Russell, I. J., Diri, E. W., Duan, W. R., Young, J. P., Sharma, U., Martin, S. A., Barrett, J. A., & Haig, G. (2008) · The Journal of Pain · doi:10.1016/j.jpain.2008.03.013 · Cited by 277
Crofford, L. J., Mease, P. J., Simpson, S. L., Young, J. P., Martin, S. A., Haig, G. M., & Sharma, U. (2008) · Pain · doi:10.1016/j.pain.2008.02.027 · Cited by 236 · cited 1×
“2006] and the management of fibromyalgia [Arnold et al. 2008; Crofford et al. 2008; Mease et al. 2008; Ohta et al. 2012; Pauer et al. 2011, 2012] in North America.”
Role of Branched‐Chain Aminotransferase Isoenzymes and Gabapentin in Neurotransmitter Metabolism
Hutson, S. M., Berkich, D., Drown, P., Xu, B., Aschner, M., & LaNoue, K. F. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.71020863.x · Cited by 171
Baron, R., Freynhagen, R., Tölle, T. R., Cloutier, C., Leon, T., Murphy, K. T., & Phillips, K. (2010) · Pain · doi:10.1016/j.pain.2010.04.013 · Cited by 163 · cited 2×
“A double-blind, placebo-substitution study evaluated the time to loss of pain relief response in patients with lumbosacral radiculopathy causing low back pain whose condition had previously responded to PGB using a single-blind, 4-week exposure to PGB [Baron et al. 2010].”
MethodBramness, J. G., Sandvik, P., Engeland, A., & Skurtveit, S. (2010) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/j.1742-7843.2010.00590.x · Cited by 37
Cited by
Skvarc, D. R., Berk, M., Byrne, L. K., Dean, O. M., Dodd, S., Lewis, M., Marriott, A., Moore, E. M., Morris, G., Page, R. S., et al. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.11.011 · Cited by 312
Dronabinol Is a Safe Long-Term Treatment Option for Neuropathic Pain Patients
Schimrigk, S., Marziniak, M., Neubauer, C., Kugler, E. M., Werner, G., & Abramov-Sommariva, D. (2017) · European Neurology · doi:10.1159/000481089 · Cited by 136
Millan, M. J., Goodwin, G. M., Meyer-Lindenberg, A., & Ove Ögren, S. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.016 · Cited by 132
Treating pain in diabetic neuropathy: current and developmental drugs
Alam, U., Sloan, G., & Tesfaye, S. (2020) · Drugs · doi:10.1007/s40265-020-01259-2 · Cited by 104
“Alternative anti-neuropathic agents with theoretical superior cardiovascular safety profile should instead be considered, for example duloxetine and pregabalin [202, 203].”
Background
Metadata
- Authors
- Toth, C.
- Venue
- Therapeutic Advances in Drug Safety
- Publisher
- SAGE Publications
- Published
- 2013-09-20
- Volume
- 5
- Issue
- 1
- Pages
- 38-56
- ISSN
- 2042-0986 (ISSN-L)
- 2042-0994
- OpenAlex
- W2159872359
- Cited by
- 198
- References
- 7
- FWCI
- 5.30
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain. https://app.cochat.ai/papers/10.1177/2042098613505614
- The paper
- Toth, C. (2014). Pregabalin: latest safety evidence and clinical implications for the management of neuropathic pain. Therapeutic Advances in Drug Safety. https://doi.org/10.1177/2042098613505614
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.